Table 3 VE of three doses of mRNA-1273 against infection with Delta or Omicron variants by subgroup

From: Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants

 

SARS-CoV-2 test positive

SARS-CoV-2 test negative

VE (95% CI)

 

Varianta,b

Vaccinated (%)

Unvaccinated (%)

Vaccinated (%)

Unvaccinated (%)

Unadjusted

Adjusted

P value for interaction

Delta

       

 Age at specimen collection date

      

0.3742

 <65

94 (3.4%)

2,694 (96.6%)

1,470 (26.4%)

4,106 (73.6%)

93.3% (91.3%, 94.8%)

94.3% (92.5%, 95.7%)

 

 ≥65

44 (18.9%)

189 (81.1%)

366 (78.5%)

100 (21.5%)

95.0% (91.1%, 97.1%)

96.0% (92.3%, 97.9%)

 

 Sex

      

0.8922

 Female

75 (4.7%)

1,519 (95.3%)

969 (30.4%)

2,219 (69.6%)

93.2% (90.7%, 95.0%)

94.4% (92.2%, 96.0%)

 

 Male

63 (4.4%)

1,364 (95.6%)

867 (30.4%)

1,987 (69.6%)

94.2% (91.7%, 95.9%)

94.6% (92.0%, 96.3%)

 

 Race/ethnicity

      

0.1993

 Hispanic

39 (3.0%)

1,240 (97.0%)

577 (22.6%)

1,981 (77.4%)

92.4% (88.7%, 94.8%)

93.1% (89.4%, 95.5%)

 

 Non-Hispanic and others

99 (5.7%)

1,643 (94.3%)

1,259 (36.1%)

2,225 (63.9%)

94.2% (92.2%, 95.7%)

95.1% (93.2%, 96.4%)

 

 Immunocompromised status

      

0.0002

 Yesc

14 (30.4%)

32 (69.6%)

128 (52.2%)

117 (47.8%)

60.0% (21.4%, 79.7%)

70.6% (31.0%, 87.5%)

 

 No

124 (4.2%)

2,851 (95.8%)

1,708 (29.5%)

4,089 (70.5%)

89.6% (87.4%, 91.4%)

93.7% (92.2%, 94.9%)

 

Omicron

       

 Age at specimen collection date

      

0.0969

 <65

1,943 (18.9%)

8,335 (81.1%)

8,573 (41.7%)

11,983 (58.3%)

72.2% (70.4%, 73.9%)

70.9% (68.9%, 72.9%)

 

 ≥65

674 (71.8%)

265 (28.2%)

1,630 (86.8%)

248 (13.2%)

61.7% (53.2%, 68.6%)

64.3% (55.0%, 71.7%)

 

 Sex

      

0.9159

 Female

1,529 (24.1%)

4,816 (75.9%)

5,862 (46.2%)

6,828 (53.8%)

70.4% (67.9%, 72.6%)

70.0% (67.4%, 72.4%)

 

 Male

1,088 (22.3%)

3,784 (77.7%)

4,341 (44.6%)

5,403 (55.4%)

72.9% (70.3%, 75.3%)

70.0% (66.6%, 72.9%)

 

 Race/ethnicity

      

0.0866

 Hispanic

970 (18.9%)

4,157 (81.1%)

3,976 (38.8%)

6,278 (61.2%)

69.6% (66.7%, 72.2%)

68.0% (64.6%, 71.0%)

 

 Non-Hispanic and others

1,647 (27.0%)

4,443 (73.0%)

6,227 (51.1%)

5,953 (48.9%)

72.8% (70.5%, 74.9%)

71.4% (68.8%, 73.8%)

 

 Immunocompromised status

      

<.0001

 Yes

153 (55.8%)

121 (44.2%)

526 (63.2%)

306 (36.8%)

26.4% (3.0%, 44.2%)

29.4% (0.3%, 50.0%)

 

 No

2,464 (22.5%)

8,479 (77.5%)

9,677 (44.8%)

11,925 (55.2%)

64.2% (62.3%, 66.0%)

70.5% (68.6%, 72.4%)

 
  1. aModels for immunocompromised status subgroup analyses are unconditional logistic models with adjustment for matching variables.
  2. bModel adjusted for core variables: history of SARS-CoV-2 molecular test; preventive care; number of outpatient and virtual visits; Charlson comorbidity score; obesity (yes/no/unknown); frailty index; specimen type; immunocompromised status and history of COVID-19
  3. cNumber of outpatient and virtual visits was removed from the list of core variables owing to lack of model convergence.
Back to article page